<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="stress, PUFA abundance and composition became of great interest in" exact="neurodegeneration" post="studies because of PUFA’s high propensity to oxidize. The"/>
 <result pre="disorders and PD development. alpha-synuclein Parkinson’s disease polyunsaturated fatty acids" exact="neurodegeneration" post="1. Introduction Parkinson’s disease (PD) is a progressive, neurodegenerative"/>
 <result pre="The key event in neurons that leads to PD and" exact="neurodegeneration" post="is not defined, and several pathways that underlie both"/>
 <result pre="higher than normal [ 10] and, anyway, altered in various" exact="neurological disorder" post="[ 11]. In particular, the levels of those PUFA-derived"/>
 <result pre="α-syn-soluble oligomers as precursors of the insoluble aggregates associated with" exact="neurodegeneration" post="[ 17]. Further, the same group in another work"/>
 <result pre="the formation of α-syn aggregates resembling the inclusion observed in" exact="neurodegeneration" post="upon exposure to DHA was observed, which was incorporated"/>
 <result pre="in the onset of PD and more in general in" exact="neurodegeneration" post="is far from being understood. The interplay between α-syn"/>
 <result pre="form are elevated in patients affected by PD or LB" exact="dementia" post="[ 13]. However, the question is still debated, since"/>
 <result pre="new mutation, E46K, of α-synuclein causes Parkinson and Lewy body" exact="dementia" post="Ann. Neurol. 2004 55 164 173 10.1002/ana.10795 14755719 4."/>
 <result pre="in filamentous inclusions of Lewy bodies from Parkinson's disease and" exact="dementia" post="with Lewy bodies Proc. Natl. Acad. Sci. USA 1998"/>
</results>
